Vascular Biogenics Ltd. (NASDAQ:VBLT) tinted loss of -0.93% (-0.02 points) to US$2.65. The volume of 0.11 Million shares climbed down over an trading activity of 274.19 Million shares. EPS ratio determined by looking at last 12 month figures is -0.44. Over the same time span, the stock marked US$9.05 as its best level and the lowest price reached was US$2. The corporation has a market cap of US$94.98 Million.
Vascular Biogenics Ltd. (NASDAQ:VBLT)’s earnings per share has been growing at a 10.9 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -28.7 percent while most common profitability ratio return on investment (ROI) was -19.1 percent. The company’s institutional ownership is monitored at 27.1 percent. The company’s net profit margin has achieved the current level of -87.6 percent and possesses 97.1 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 3 think it is Hold. Recently, analysts have updated the overall rating to 3. 0 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Cidara Therapeutics, Inc. (NASDAQ:CDTX) is worth US$122.8 Million and has recently fallen -0.93% to US$5.3. The latest exchange of 0.11 Million shares is below its average trading activity of 267.64 Million shares. The day began at US$0 but the price moved to US$5.25 at one point during the trading and finally capitulating to a session high of US$5.25. The stock tapped a 52-week high of US$8.8 while the mean 12-month price target for the shares is US$14.31.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 2.17, and a price to sales ratio of 0. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 75.1%, it carries an earnings per share ratio of -3.21.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 4 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 3 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.43.